tiprankstipranks
Trending News
More News >
CareDx (CDNA)
NASDAQ:CDNA
US Market
Advertisement

CareDx (CDNA) Stock Forecast & Price Target

Compare
823 Followers
See the Price Targets and Ratings of:

CDNA Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
3 Buy
5 Hold
0 Sell
Based on 8 analysts giving stock ratings to
CareDx
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CDNA Stock 12 Month Forecast

Average Price Target

$19.13
▲(38.42% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for CareDx in the last 3 months. The average price target is $19.13 with a high forecast of $28.00 and a low forecast of $12.50. The average price target represents a 38.42% change from the last price of $13.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","16":"$16","21":"$21","26":"$26","31":"$31"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,16,21,26,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.22,13.433846153846154,14.647692307692308,15.861538461538462,17.075384615384614,18.28923076923077,19.503076923076925,20.716923076923077,21.93076923076923,23.144615384615385,24.35846153846154,25.572307692307692,26.786153846153844,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.22,12.751538461538463,13.283076923076923,13.814615384615385,14.346153846153847,14.877692307692307,15.409230769230769,15.94076923076923,16.47230769230769,17.003846153846155,17.535384615384615,18.066923076923075,18.598461538461535,{"y":19.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.22,12.241538461538463,12.263076923076923,12.284615384615385,12.306153846153846,12.327692307692308,12.34923076923077,12.37076923076923,12.392307692307693,12.413846153846155,12.435384615384615,12.456923076923077,12.478461538461538,{"y":12.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.58,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.73,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.64,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.41,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$28.00Average Price Target$19.13Lowest Price Target$12.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on CDNA
TR | OpenAI - 4o
TR | OpenAI - 4o
$12.5
Hold
-9.55%
Downside
Reiterated
08/28/25
AI Generated ArticleAI Generated Article
William Blair Analyst forecast on CDNA
William Blair
William Blair
Hold
Initiated
08/25/25
Hold Rating for CareDx Amid Revenue Uncertainties and Valuation DiscountWe believe the company’s synergistic and expanding portfolio of offerings, transplant cases growing in the midsingle digits annually, tailwinds from government initiatives like the IOTA (Increasing Organ Transplant Access) model, and CareDx’s leading share in the testing services are the ingredients for sticky, predictable, and profitable revenue growth. Better days ahead. CareDx has seen significant business pressures in recent history, including (ongoing) reimbursement headaches, patent litigation and securities investigations, and changes in the executive suite. Downside potential related to the draft LCD is likely priced in, but shares may be in a holding pattern until it is finalized. When this happens, shares could rebase and move much higher.Attractive financial profile.
Raymond James Analyst forecast on CDNA
Unknown Analyst
Raymond James
Not Ranked
Raymond James
Hold
Reiterated
08/22/25
Raymond James Remains a Hold on CareDx (CDNA)
BTIG
$26$22
Buy
59.19%
Upside
Reiterated
08/13/25
BTIG Sticks to Its Buy Rating for CareDx (CDNA)
Wells Fargo
$19$14
Hold
1.30%
Upside
Reiterated
08/08/25
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (NASDAQ: RCKT), CareDx (NASDAQ: CDNA) and Insulet (NASDAQ: PODD)
H.C. Wainwright Analyst forecast on CDNA
H.C. Wainwright
H.C. Wainwright
Hold
Reiterated
08/08/25
CareDx Faces Financial Challenges Amid Mixed Signals and Policy Uncertainties
Craig-Hallum Analyst forecast on CDNA
Craig-Hallum
Craig-Hallum
Buy
Reiterated
08/07/25
Craig-Hallum Sticks to Their Buy Rating for CareDx (CDNA)
Nephron Analyst forecast on CDNA
Thomas DeBourcy
Nephron
Not Ranked
Nephron
$28
Buy
102.60%
Upside
Upgraded
07/09/25
CareDx upgraded to Buy from Hold at Nephron ResearchCareDx upgraded to Buy from Hold at Nephron Research
Goldman Sachs Analyst forecast on CDNA
Goldman Sachs
Goldman Sachs
$34$26
Buy
88.13%
Upside
Reiterated
04/16/25
CareDx, Inc (CDNA) PT Lowered to $26 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on CareDx, Inc (NASDAQ: CDNA) to $26.00 (from $34.00) while maintaining a Buy rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on CDNA
TR | OpenAI - 4o
TR | OpenAI - 4o
$12.5
Hold
-9.55%
Downside
Reiterated
08/28/25
AI Generated ArticleAI Generated Article
William Blair Analyst forecast on CDNA
William Blair
William Blair
Hold
Initiated
08/25/25
Hold Rating for CareDx Amid Revenue Uncertainties and Valuation DiscountWe believe the company’s synergistic and expanding portfolio of offerings, transplant cases growing in the midsingle digits annually, tailwinds from government initiatives like the IOTA (Increasing Organ Transplant Access) model, and CareDx’s leading share in the testing services are the ingredients for sticky, predictable, and profitable revenue growth. Better days ahead. CareDx has seen significant business pressures in recent history, including (ongoing) reimbursement headaches, patent litigation and securities investigations, and changes in the executive suite. Downside potential related to the draft LCD is likely priced in, but shares may be in a holding pattern until it is finalized. When this happens, shares could rebase and move much higher.Attractive financial profile.
Raymond James Analyst forecast on CDNA
Unknown Analyst
Raymond James
Not Ranked
Raymond James
Hold
Reiterated
08/22/25
Raymond James Remains a Hold on CareDx (CDNA)
BTIG
$26$22
Buy
59.19%
Upside
Reiterated
08/13/25
BTIG Sticks to Its Buy Rating for CareDx (CDNA)
Wells Fargo
$19$14
Hold
1.30%
Upside
Reiterated
08/08/25
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (NASDAQ: RCKT), CareDx (NASDAQ: CDNA) and Insulet (NASDAQ: PODD)
H.C. Wainwright Analyst forecast on CDNA
H.C. Wainwright
H.C. Wainwright
Hold
Reiterated
08/08/25
CareDx Faces Financial Challenges Amid Mixed Signals and Policy Uncertainties
Craig-Hallum Analyst forecast on CDNA
Craig-Hallum
Craig-Hallum
Buy
Reiterated
08/07/25
Craig-Hallum Sticks to Their Buy Rating for CareDx (CDNA)
Nephron Analyst forecast on CDNA
Thomas DeBourcy
Nephron
Not Ranked
Nephron
$28
Buy
102.60%
Upside
Upgraded
07/09/25
CareDx upgraded to Buy from Hold at Nephron ResearchCareDx upgraded to Buy from Hold at Nephron Research
Goldman Sachs Analyst forecast on CDNA
Goldman Sachs
Goldman Sachs
$34$26
Buy
88.13%
Upside
Reiterated
04/16/25
CareDx, Inc (CDNA) PT Lowered to $26 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on CareDx, Inc (NASDAQ: CDNA) to $26.00 (from $34.00) while maintaining a Buy rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CareDx

1 Month
xxx
Success Rate
5/19 ratings generated profit
26%
Average Return
-9.20%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 26.32% of your transactions generating a profit, with an average return of -9.20% per trade.
3 Months
xxx
Success Rate
6/19 ratings generated profit
32%
Average Return
-15.73%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 31.58% of your transactions generating a profit, with an average return of -15.73% per trade.
1 Year
William BonelloCraig-Hallum
Success Rate
4/11 ratings generated profit
36%
Average Return
-11.65%
reiterated a buy rating last month
Copying William Bonello's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -11.65% per trade.
2 Years
xxx
Success Rate
2/19 ratings generated profit
11%
Average Return
-47.93%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 10.53% of your transactions generating a profit, with an average return of -47.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CDNA Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
2
4
3
6
4
Buy
3
2
4
8
9
Hold
5
6
5
6
11
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
10
13
13
21
24
In the current month, CDNA has received 13 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. CDNA average Analyst price target in the past 3 months is 19.13.
Each month's total comprises the sum of three months' worth of ratings.

CDNA Financial Forecast

CDNA Earnings Forecast

Next quarter’s earnings estimate for CDNA is -$0.08 with a range of -$0.14 to -$0.03. The previous quarter’s EPS was -$0.16. CDNA beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.16% of the time in the same period. In the last calendar year CDNA has Outperformed its overall industry.
Next quarter’s earnings estimate for CDNA is -$0.08 with a range of -$0.14 to -$0.03. The previous quarter’s EPS was -$0.16. CDNA beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.16% of the time in the same period. In the last calendar year CDNA has Outperformed its overall industry.

CDNA Sales Forecast

Next quarter’s sales forecast for CDNA is $95.32M with a range of $93.69M to $96.52M. The previous quarter’s sales results were $86.68M. CDNA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.23% of the time in the same period. In the last calendar year CDNA has Outperformed its overall industry.
Next quarter’s sales forecast for CDNA is $95.32M with a range of $93.69M to $96.52M. The previous quarter’s sales results were $86.68M. CDNA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.23% of the time in the same period. In the last calendar year CDNA has Outperformed its overall industry.

CDNA Stock Forecast FAQ

What is CDNA’s average 12-month price target, according to analysts?
Based on analyst ratings, CareDx’s 12-month average price target is 19.13.
    What is CDNA’s upside potential, based on the analysts’ average price target?
    CareDx has 38.42% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CDNA a Buy, Sell or Hold?
          CareDx has a consensus rating of Moderate Buy which is based on 3 buy ratings, 5 hold ratings and 0 sell ratings.
            What is CareDx’s price target?
            The average price target for CareDx is 19.13. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $28.00 ,the lowest forecast is $12.50. The average price target represents 38.42% Increase from the current price of $13.82.
              What do analysts say about CareDx?
              CareDx’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of CDNA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis